UPDATE: Goldman Sachs Starts TG Therapeutics (TGTX) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to UPDATE: Goldman Sachs Starts TG Therapeutics (TGTX) at Neutral
April 21, 2021 7:04 AM EDT
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the initiation of patient enrollment into the ULTRA-V Phase 3 randomized trial, evaluating the time-limited triple combination of UKONIQ (umbralisib), the Companys once-daily, inhibitor of PI3K-delta and CK1-epsilon, ublituximab, the Companys investigational glycoengineered anti-CD20 monoclonal antibody, and venetoclax, compared to the continuous doublet combination of UKONIQ plus ublituximab (U2) in patients with both frontline and relapsed or refractory chronic lymphocytic leukemia (CLL). The primary endpoint for the ULTRA-V Phase 3 trial is Progression-free Survival (PFS), and the trial is designed support the full approval of... More
April 19, 2021 6:32 AM EDT
H.C. Wainwright analyst Edward P. White raised the price target on TG Therapeutics (NASDAQ: TGTX) to $89.00 (from $79.00) while maintaining a Buy rating.... More
April 16, 2021 7:32 AM EDT
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced positive results from two global, active-controlled, Phase 3 studies, called ULTIMATE I & II, evaluating ublituximab, the Companys investigational novel, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide, in patients with relapsing forms of multiple sclerosis (RMS). Both studies met... More
